_id
6915eed4bc934aba376b1ee6
Ticker
RICFY
Name
Recordati Industria Chimica e Farmaceutica S.p.A.
Exchange
PINK
Address
Via Matteo Civitali,1, Milan, MI, Italy, 20148
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - General
Currency
USD
Website
https://recordati.com
Description
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing's syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, a throat spray; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; REC 0559 for neurotrophic keratitis; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. Recordati Industria Chimica e Farmaceutica S.p.A. was founded in 1926 and is headquartered in Milan, Italy.
Last Close
13.95
Volume
176
Current Price
14.25
Change
0
Last Updated
2025-12-03T12:56:19.214Z
Image
data:image/webp;base64,UklGRswIAABXRUJQVlA4WAoAAAAQAAAAPwAAPwAAQUxQSMkCAAABoK3tnyFJ+v0jqnrsmbVtWzcwOFrryMYV2LYPbdu2be/Yqoz///87KGVG3EBETABqDCNA2Gi34+754N/VTvrKP16/7vCdpwEYCcgxAJsfdd1fHPrTK+ZMg4TGAgL2v/17OlXNvZe7qpHp44s3g4g0IQHY8sHl9FQZh3XrKO3/a9dBiA20MfWytWRSZ62elFxw2ji06hJpzfmVZsYGzZ1v7oZYjwBXraWyaU/872RAaggY8whVmWEyXhckDBWw/rusnFma8oHxCEMINvqcyZmpV3x8DGQgwZi3qMxYeS8gA0jAo0zMWnkN4gARVzExb3c7Aa0+EYe6eWY0zt0TsYdgo99pzD7xhfGQLuAaJhaYeHqfbSoW6Zy7DgBEPEkvgs5rERFxyJJSjH9tgjCCe1ixUOUFaGOH32mlJL43FTiWFUt14yzg1oLY4eXYfAG9HOXH0/ekslw37nheUUw8/AlaScYrvqGX5HxqIYt2ft0pi1zghZmycPXSknlhmtYUxgVz6SU5v/6stKfvpZVkvPJ4aklrecQuZSl3XP8HWjmJH03H5azKWc0rgcOZvBQ3zgbW+4RaSuL7UzGCq5gK8Q4vQjtgi39ohfhfmyIg4iZ6Gat5AyIArLuYZfrc9dAtOJNVCat5NqTX5DeZ8kt8aUIvROw1n5ab+fy9ENG7hZPMPC9faaeghf4RNzLltZI3IGJAAR6iZuRr+QAgg0Aw9klWnouv5NNjIRg8YPxDVMtDV/GhcQgYNki4jpZySMYbowQML8DJ/zF5U97h3FMBQa0Ru71Od2vC1yrf2B0Bdbcw7rR5pCavx1MyzjtjHFqoPwasc81/Ru2oD+NpjVH/u2E9SECTIoLNzv+wQ7qqu3e5u1VGdj66YDOICJoOgqkzr/hY2W2uym77+KpZUyEBOYY2gKk7HX7lU18tUHq14Ounrjxip6kA2gE1AgBWUDgg3AUAABAXAJ0BKkAAQAA+rUKaSaYjoiEz+ZwAwBWJbACxJUFUHlpmN3/3QTYbfjymuZecP5gHOG8wHm5+gD0AP8B1IPoAeW/7K397/51s7bv/ynQLJH37ZRz1nzL+uGs++I9Cjnj+oOBz+0foqnmxW9lI+YNhpL+GmryMVVq9yNhsIlUdCQ588mZF4LhDyw8ba5VIlQohJbs+YgEC+CFRhksVdfYJoLA4UrXm7/hZln8Pq2tTDQfUJNbz/+wx/Gqi+oy2gAAA/v1ScQhVGi439hxSW2lLneqYEYUs1vwkO8bmiGpvuEuaNNImKnxE6O6334h22ERMHQdD/jKhFtw/nin3o1pE6oKRbHkjxNJ6LWCs+ECah9o1+5lBibx/1QV+5Lv5Z8804rNZGr/MTyyMHrwMX/+TYcwkJTbEm/ntgfYZFQC37tJy799184Otet+9VKG7zgtVH+KiwtsA8zWMeEtoeLeNjwHFl36PTgi5xWndd/eh2XxfcGLB+Rcd+sMXdIo0D7hf/ZhlGJUnOrIBGuOEfl1kkE8/bOvmKGzXZwOPuVLL8gALvNmP0dxJFahGBiqFW5KrxPiXHti8NxCBHXTAu4/zkEO5I4kITho+QKbVP/+612FO8/+Gb7aSdSBOPYlYSPRMHdItMQKqyK81LB5OdOd5COAXh1KBt7BoTyYQlnyBHPL86w6O0c7WGTppb93J3RuqNHqhrAXfQ/Hq4FLJm/Q+T5udT2Tc7kRyGJteTSV4lu8WOCEVRzA5y9S9XvyDZc98Rcrya6GtMXWQUTLwty41OTyEg8GWG3611ciCQNWrwiIrbA1NaTlw6U3sCNoShZbqt1BxoNFtT3ZOzxA7zuolP8rJ4pQD//dhUwR+h5yVzmRr7hnvd3t7PVcvMklPALRNpKJFBw21mBL9nMdf0my9EsFLRO8TF9OPpecbc1XgkzXqRQflsPLrS43kNwhr956K1fR5Q//0a0TGSZZCgULrT9HrzWi/44v7omx1jClcpHfPEytiyksI03Ogk+lhaDlFtg3ezNI80djFBf3HY38O7NsZ0ndCkdB3WX2JWRu96/nbkn03uZxRnniFQ8Ux7UGVzflR6zMkA0tXZS7v4DmxI774NGGcsiFPfjzxIhkt/ZKQsH4Gx0D5lUmkwQ341p9KTxJ6ppUwGncQsHe//g8IKBQ9HxV3V9WDm+wfSnhH1DjuxNSd8m3xHLPEf9+e/GEwJAaVb7u2wZcKgXdHx9jWu9cyL3dLX+L4S4rx2pkiiWd/dk8IV1NTrse3UP+tR3l7oTriOTV6MPc2zdt7f1u//v0+gPZqwS6sYWGhOU9+/zlLJbF0PnaUd6mJP8fHs9qMor754ozvkrZNXLwPuduyfuZnN6n2iMbOBmmo3YoAapdC1kI8/zVY+X3P+Vp+8cc7DD9XD6Mm1ydXfXqsKAK0pe6bpBzXVvtxj/TWf1nAIHpGgQiVG995FBLxy6mMednpxZ/iPHBwocncnNNVX4CJeQXbRzCG5j6a/PPInVpE2LrfAm4dnnZMAK8yLHywLYUheq2zsX4NRVR4ILq+PHS9yQUISblgJi79ujECR6hBTd4QcNqySWeY+a4LvwnWFMCCz3eUx9bZ2Dtw7Lui2TZtIEF7FVaWJj2M3RJoHsyu3aPC/gJxzOBo1WLNc4YQNfAZ5WQo7nZumJWQrXZB+6zJ4vBZSa9Yxlk41hLlVPoKicyesKqh4nQBQrb/LbWjOV2ZvTV3Tm01ioiR5YNUoJNXT9HlLXYhm7+xat3By5xT/Fy6gOj3fHoJnJModh1Sodieh1x6ByDXa9fwDXQpNOeNKOokS7F7BrAeHsAlTzxALNih0hiXZ6y9DzeBvE/N85EAOGHgRluc2J89ODFGF4AkPlDJdRavVuinmIavS0xtWBDb/m15D4sxXK4gMAPGCUA6yJPInppJTltFeByiNaK7Q/DNIdtORdAuN76jr0IVPTVk3hJm/Pow5EDAVL7BhmMeq+pf7QX4T0AAAA==
Ipo Date
-
Market Cap
11570023424
Next Dividend Date
2025-12-11T00:00:00.000Z
Dividend Frequency
Semiannual
Dividend Rate
0.09861
Dividend Yield
2.768
Sentiment
0.9986666666666667
Sentiment Sources
3
Current Quarter
2025-09-30
Revenue
632321000
Cost Of Revenue
199913000
Gross Profit
432408000
Operating Expenses
451340000
Operating Income
180981000
Interest Expense
23232000
Pretax Income
144949000
Net Income
110165000
Eps
0.538532971463032
Dividends Per Share
900000
Shares Outstanding
817587664
Income Tax Expense
-
EBITDA
-
Operating Margin
28.621696891294135
Total Other Income Expense Net
-
Cash
471462000
Short Term Investments
-
Receivables
574044000
Inventories
505195000
Total Current Assets
1713815000
Property Plant Equipment
213801000
Total Assets
5298719000
Payables
315050000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
3370878000
Equity
1927841000
Depreciation
51137000
Change In Working Capital
-34675000
Cash From Operations
152157000
Capital Expenditures
14715000
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
129287000
PE
24.9107
PB
1.512080779094334
ROE
5.714423544265321
ROA
2.0790874171663
FCF
137442000
Fcf Percent
0.21736111879883793
Piotroski FScore
4
Health Score
66
Deep Value Investing Score
5
Defensive Investing Score
8
Dividend Investing Score
4
Economic Moat Investing Score
7.3
Garp Investing Score
5
Growth Investing Score
4.5
Momentum Investing Score
4
Net Net Investing Score
4
Quality Investing Score
7
Value Investing Score
7.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
632321000
Quarters > 0 > income Statement > cost Of Revenue
199913000
Quarters > 0 > income Statement > gross Profit
432408000
Quarters > 0 > income Statement > operating Expenses
451340000
Quarters > 0 > income Statement > operating Income
180981000
Quarters > 0 > income Statement > interest Expense
23232000
Quarters > 0 > income Statement > pretax Income
144949000
Quarters > 0 > income Statement > net Income
110165000
Quarters > 0 > income Statement > eps
0.538532971463032
Quarters > 0 > income Statement > dividends Per Share
900000
Quarters > 0 > income Statement > shares Outstanding
204565005
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
28.621696891294135
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
471462000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
574044000
Quarters > 0 > balance Sheet > inventories
505195000
Quarters > 0 > balance Sheet > total Current Assets
1713815000
Quarters > 0 > balance Sheet > property Plant Equipment
213801000
Quarters > 0 > balance Sheet > total Assets
5298719000
Quarters > 0 > balance Sheet > payables
315050000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
3370878000
Quarters > 0 > balance Sheet > equity
1927841000
Quarters > 0 > cash Flow > net Income
110165000
Quarters > 0 > cash Flow > depreciation
51137000
Quarters > 0 > cash Flow > change In Working Capital
-34675000
Quarters > 0 > cash Flow > cash From Operations
152157000
Quarters > 0 > cash Flow > capital Expenditures
14715000
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
129287000
Quarters > 0 > ratios > PE
0.538532971463032
Quarters > 0 > ratios > PB
1.512080779094334
Quarters > 0 > ratios > ROE
5.714423544265321
Quarters > 0 > ratios > ROA
2.0790874171663
Quarters > 0 > ratios > FCF
137442000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.21736111879883793
Quarters > 0 > health Score
66
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
643882000
Quarters > 1 > income Statement > cost Of Revenue
220032000
Quarters > 1 > income Statement > gross Profit
423850000
Quarters > 1 > income Statement > operating Expenses
493931000
Quarters > 1 > income Statement > operating Income
149951000
Quarters > 1 > income Statement > interest Expense
24437000
Quarters > 1 > income Statement > pretax Income
119491000
Quarters > 1 > income Statement > net Income
91080000
Quarters > 1 > income Statement > eps
0.44308484444781193
Quarters > 1 > income Statement > dividends Per Share
136534000
Quarters > 1 > income Statement > shares Outstanding
205558825
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
23.288583933080904
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
341550000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
588994000
Quarters > 1 > balance Sheet > inventories
493628000
Quarters > 1 > balance Sheet > total Current Assets
1569500000
Quarters > 1 > balance Sheet > property Plant Equipment
206820000
Quarters > 1 > balance Sheet > total Assets
5176136000
Quarters > 1 > balance Sheet > payables
330218000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
3305614000
Quarters > 1 > balance Sheet > equity
1870522000
Quarters > 1 > cash Flow > net Income
91080000
Quarters > 1 > cash Flow > depreciation
50721000
Quarters > 1 > cash Flow > change In Working Capital
-50580000
Quarters > 1 > cash Flow > cash From Operations
107383000
Quarters > 1 > cash Flow > capital Expenditures
34542000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
14603000
Quarters > 1 > ratios > PE
0.44308484444781193
Quarters > 1 > ratios > PB
1.5659870647070713
Quarters > 1 > ratios > ROE
4.869229017354513
Quarters > 1 > ratios > ROA
1.7596137350332373
Quarters > 1 > ratios > FCF
72841000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.11312787125591335
Quarters > 1 > health Score
56
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
679960000
Quarters > 2 > income Statement > cost Of Revenue
221188000
Quarters > 2 > income Statement > gross Profit
458772000
Quarters > 2 > income Statement > operating Expenses
482779000
Quarters > 2 > income Statement > operating Income
197181000
Quarters > 2 > income Statement > interest Expense
26390000
Quarters > 2 > income Statement > pretax Income
164860000
Quarters > 2 > income Statement > net Income
125041000
Quarters > 2 > income Statement > eps
0.6070113463513701
Quarters > 2 > income Statement > dividends Per Share
1086000
Quarters > 2 > income Statement > shares Outstanding
205994502
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
28.998911700688275
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
333044000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
603646000
Quarters > 2 > balance Sheet > inventories
488192000
Quarters > 2 > balance Sheet > total Current Assets
1565880000
Quarters > 2 > balance Sheet > property Plant Equipment
203758000
Quarters > 2 > balance Sheet > total Assets
5166142000
Quarters > 2 > balance Sheet > payables
334446000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
3188444000
Quarters > 2 > balance Sheet > equity
1977698000
Quarters > 2 > cash Flow > net Income
125041000
Quarters > 2 > cash Flow > depreciation
50922000
Quarters > 2 > cash Flow > change In Working Capital
-52271000
Quarters > 2 > cash Flow > cash From Operations
164789000
Quarters > 2 > cash Flow > capital Expenditures
8532000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
12365000
Quarters > 2 > ratios > PE
0.6070113463513701
Quarters > 2 > ratios > PB
1.4842618304210247
Quarters > 2 > ratios > ROE
6.322552786118002
Quarters > 2 > ratios > ROA
2.420394174221305
Quarters > 2 > ratios > FCF
156257000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.2298032237190423
Quarters > 2 > health Score
67
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
598478000
Quarters > 3 > income Statement > cost Of Revenue
185116000
Quarters > 3 > income Statement > gross Profit
413362000
Quarters > 3 > income Statement > operating Expenses
449681000
Quarters > 3 > income Statement > operating Income
148797000
Quarters > 3 > income Statement > interest Expense
21547000
Quarters > 3 > income Statement > pretax Income
105405000
Quarters > 3 > income Statement > net Income
78108000
Quarters > 3 > income Statement > eps
0.37862057928492976
Quarters > 3 > income Statement > dividends Per Share
123498000
Quarters > 3 > income Statement > shares Outstanding
206296235
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
24.862568047614115
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
322423000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
516743000
Quarters > 3 > balance Sheet > inventories
506447000
Quarters > 3 > balance Sheet > total Current Assets
1491400000
Quarters > 3 > balance Sheet > property Plant Equipment
206700000
Quarters > 3 > balance Sheet > total Assets
5134455000
Quarters > 3 > balance Sheet > payables
296698000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
3257646000
Quarters > 3 > balance Sheet > equity
1876809000
Quarters > 3 > cash Flow > net Income
78100000
Quarters > 3 > cash Flow > depreciation
45431000
Quarters > 3 > cash Flow > change In Working Capital
-48511000
Quarters > 3 > cash Flow > cash From Operations
115288000
Quarters > 3 > cash Flow > capital Expenditures
814041000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-
Quarters > 3 > cash Flow > net Change In Cash
84753000
Quarters > 3 > ratios > PE
0.37862057928492976
Quarters > 3 > ratios > PB
1.5663401809933777
Quarters > 3 > ratios > ROE
4.161744748666487
Quarters > 3 > ratios > ROA
1.521252012141503
Quarters > 3 > ratios > FCF
-698753000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
-1.1675500185470478
Quarters > 3 > health Score
46
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
2341559000
Annuals > 0 > income Statement > cost Of Revenue
741287000
Annuals > 0 > income Statement > gross Profit
1600272000
Annuals > 0 > income Statement > operating Expenses
1681689000
Annuals > 0 > income Statement > operating Income
659870000
Annuals > 0 > income Statement > interest Expense
81161000
Annuals > 0 > income Statement > pretax Income
547184000
Annuals > 0 > income Statement > net Income
416508000
Annuals > 0 > income Statement > eps
2.0189801331081005
Annuals > 0 > income Statement > dividends Per Share
253718000
Annuals > 0 > income Statement > shares Outstanding
206296235
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
28.180797494318956
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > balance Sheet > cash
322423000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
516743000
Annuals > 0 > balance Sheet > inventories
506447000
Annuals > 0 > balance Sheet > total Current Assets
1491400000
Annuals > 0 > balance Sheet > property Plant Equipment
206700000
Annuals > 0 > balance Sheet > total Assets
5134455000
Annuals > 0 > balance Sheet > payables
296698000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
3257646000
Annuals > 0 > balance Sheet > equity
1876809000
Annuals > 0 > cash Flow > net Income
416508000
Annuals > 0 > cash Flow > depreciation
167025000
Annuals > 0 > cash Flow > change In Working Capital
-112519000
Annuals > 0 > cash Flow > cash From Operations
569918000
Annuals > 0 > cash Flow > capital Expenditures
851161000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
97090000
Annuals > 0 > ratios > PE
2.0189801331081005
Annuals > 0 > ratios > PB
1.5358267750815346
Annuals > 0 > ratios > ROE
22.192348821856672
Annuals > 0 > ratios > ROA
8.112019678816933
Annuals > 0 > ratios > FCF
-281243000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
-0.12010929470493803
Annuals > 0 > health Score
65
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
2082331000
Annuals > 1 > income Statement > cost Of Revenue
659707000
Annuals > 1 > income Statement > gross Profit
1422624000
Annuals > 1 > income Statement > operating Expenses
1516564000
Annuals > 1 > income Statement > operating Income
565767000
Annuals > 1 > income Statement > interest Expense
74455000
Annuals > 1 > income Statement > pretax Income
491036000
Annuals > 1 > income Statement > net Income
389214000
Annuals > 1 > income Statement > eps
1.8893322932088539
Annuals > 1 > income Statement > dividends Per Share
245958000
Annuals > 1 > income Statement > shares Outstanding
206006112
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
27.169887976503254
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > balance Sheet > cash
221812000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
445193000
Annuals > 1 > balance Sheet > inventories
404831000
Annuals > 1 > balance Sheet > total Current Assets
1202240000
Annuals > 1 > balance Sheet > property Plant Equipment
178657000
Annuals > 1 > balance Sheet > total Assets
4208131000
Annuals > 1 > balance Sheet > payables
263979000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
2521739000
Annuals > 1 > balance Sheet > equity
1686392000
Annuals > 1 > cash Flow > net Income
389200000
Annuals > 1 > cash Flow > depreciation
142670000
Annuals > 1 > cash Flow > change In Working Capital
-110633000
Annuals > 1 > cash Flow > cash From Operations
485319000
Annuals > 1 > cash Flow > capital Expenditures
383264000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
-
Annuals > 1 > cash Flow > net Change In Cash
-63213000
Annuals > 1 > ratios > PE
1.8893322932088539
Annuals > 1 > ratios > PB
1.706839097498565
Annuals > 1 > ratios > ROE
23.079687285044045
Annuals > 1 > ratios > ROA
9.249094194073331
Annuals > 1 > ratios > FCF
102055000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.04900997968142433
Annuals > 1 > health Score
69
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
1853307000
Annuals > 2 > income Statement > cost Of Revenue
566737000
Annuals > 2 > income Statement > gross Profit
1286570000
Annuals > 2 > income Statement > operating Expenses
1359142000
Annuals > 2 > income Statement > operating Income
494165000
Annuals > 2 > income Statement > interest Expense
32158000
Annuals > 2 > income Statement > pretax Income
401435000
Annuals > 2 > income Statement > net Income
312336000
Annuals > 2 > income Statement > eps
1.520318792260496
Annuals > 2 > income Statement > dividends Per Share
230602000
Annuals > 2 > income Statement > shares Outstanding
205441123
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
26.663957995086623
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > balance Sheet > cash
284734000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
361898000
Annuals > 2 > balance Sheet > inventories
424080000
Annuals > 2 > balance Sheet > total Current Assets
1186086000
Annuals > 2 > balance Sheet > property Plant Equipment
159184000
Annuals > 2 > balance Sheet > total Assets
3998823000
Annuals > 2 > balance Sheet > payables
224703000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
2452575000
Annuals > 2 > balance Sheet > equity
1546248000
Annuals > 2 > cash Flow > net Income
312300000
Annuals > 2 > cash Flow > depreciation
125756000
Annuals > 2 > cash Flow > change In Working Capital
-61387000
Annuals > 2 > cash Flow > cash From Operations
461691000
Annuals > 2 > cash Flow > capital Expenditures
96339000
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
-
Annuals > 2 > cash Flow > net Change In Cash
35844000
Annuals > 2 > ratios > PE
1.520318792260496
Annuals > 2 > ratios > PB
1.856432827725695
Annuals > 2 > ratios > ROE
20.199605755351016
Annuals > 2 > ratios > ROA
7.810698297974179
Annuals > 2 > ratios > FCF
365352000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.19713517512209255
Annuals > 2 > health Score
82
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
1580074000
Annuals > 3 > income Statement > cost Of Revenue
427727000
Annuals > 3 > income Statement > gross Profit
1152347000
Annuals > 3 > income Statement > operating Expenses
1074877000
Annuals > 3 > income Statement > operating Income
505197000
Annuals > 3 > income Statement > interest Expense
17420000
Annuals > 3 > income Statement > pretax Income
463349000
Annuals > 3 > income Statement > net Income
385966000
Annuals > 3 > income Statement > eps
1.8744324971384705
Annuals > 3 > income Statement > dividends Per Share
216742000
Annuals > 3 > income Statement > shares Outstanding
205910856
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
31.97299620144373
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > balance Sheet > cash
244578000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
307778000
Annuals > 3 > balance Sheet > inventories
228732000
Annuals > 3 > balance Sheet > total Current Assets
850101000
Annuals > 3 > balance Sheet > property Plant Equipment
131120000
Annuals > 3 > balance Sheet > total Assets
2816199000
Annuals > 3 > balance Sheet > payables
177925000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1434574000
Annuals > 3 > balance Sheet > equity
1381625000
Annuals > 3 > cash Flow > net Income
386000000
Annuals > 3 > cash Flow > depreciation
97585000
Annuals > 3 > cash Flow > change In Working Capital
20055000
Annuals > 3 > cash Flow > cash From Operations
491650000
Annuals > 3 > cash Flow > capital Expenditures
87360000
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-
Annuals > 3 > cash Flow > net Change In Cash
48208000
Annuals > 3 > ratios > PE
1.8744324971384705
Annuals > 3 > ratios > PB
2.082380417533267
Annuals > 3 > ratios > ROE
27.93565547815073
Annuals > 3 > ratios > ROA
13.705210462754941
Annuals > 3 > ratios > FCF
404290000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.2558677631553965
Annuals > 3 > health Score
84
Valuation > metrics > PE
24.9107
Valuation > metrics > PB
1.512080779094334
Valuation > final Score
100
Valuation > verdict
Fair
Profitability > metrics > ROE
5.714423544265321
Profitability > metrics > ROA
6.42805670390328
Profitability > metrics > Net Margin
0.17422321890305714
Profitability > final Score
57
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.7485249042841189
Risk > metrics > Interest Coverage
7.790160123966942
Risk > final Score
61
Risk > verdict
High
Liquidity > metrics > Current Ratio
5.4398190763370895
Liquidity > metrics > Quick Ratio
3.8362799555626093
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
100
Prev Profitabilities > 0
48
Prev Profitabilities > 1
64
Prev Profitabilities > 2
44
Prev Risks > 0
55
Prev Risks > 1
60
Prev Risks > 2
58
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:29:09.096Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-09-30
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0.154
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-06-30
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0.1234
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-07
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
EUR
Earnings History > 2 > eps Actual
0.1573
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2024-12-31
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0.0997
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-08
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
EUR
Earnings History > 4 > eps Actual
0.1483
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-07-30
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
EUR
Earnings History > 5 > eps Actual
0.1311
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-09
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
EUR
Earnings History > 6 > eps Actual
0.1604
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-02-22
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
0.1089
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-09-30
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
0.1001
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing's syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, a throat spray; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; REC 0559 for neurotrophic keratitis; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. Recordati Industria Chimica e Farmaceutica S.p.A. was founded in 1926 and is headquartered in Milan, Italy.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
0.09861Next Payout:
Dec 11, 2025Yield:
2.7680 %(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Recordati Industria Chimica e Farmaceutica S.p.A.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
0.154
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.